Connor, Clark & Lunn Investment Management Ltd. Cue Biopharma, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023
SELL
$2.39 - $3.95 $23,199 - $38,342
-9,707 Reduced 29.71%
22,970 $65,000
Q3 2022

Nov 10, 2022
BUY
$2.23 - $3.37 $72,869 - $110,121
32,677 New
32,677 $73,000

Others Institutions Holding CUE

# of Institutions
52
Shares Held
14.1M
Call Options Held
14.4K
Put Options Held
2.6K
View Full List

About Cue Biopharma, Inc.

CUE Quotes by TradingView
  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $38.2M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email